Selank: a Russian anxiolytic peptide the West has never verified

Selank sits in exactly the same category as its better-known cousin Semax: a Russian peptide with an intriguing premise, a decades-long domestic clinical history, and almost nothing the rest of the world has independently verified. It’s a synthetic analog of tuftsin, a naturally occurring immune-modulating peptide fragment, and in Russia it’s used as an anxiolytic that supposedly calms without sedating — the pitch being benzodiazepine-like relief without the grogginess, tolerance, or dependence.

That pitch is appealing, and it’s why Selank turns up constantly in nootropic forums. The honest question is whether the evidence supports it. Mostly, it can’t be checked.

What the evidence shows

The headline human study is a 2008 Russian randomized trial in generalized anxiety disorder and neurasthenia. It enrolled 62 patients — 30 on Selank, 32 on the benzodiazepine medazepam — and reported that Selank produced anxiolytic effects the authors described as comparable to medazepam, with an additional anti-asthenic effect and changes in enkephalin activity. Taken at face value, that’s a positive signal for a non-sedating anxiolytic.

But look closely at what “positive” means here. The trial is small, the reporting is thin — the available English abstract gives no effect sizes, no p-values, no responder rates, and the benzodiazepine comparison is described qualitatively rather than with hard numbers — and it has not been replicated in an independent Western trial. This is the pattern across Selank’s human literature: a handful of small domestic studies, largely in Russian-language journals, without the pre-registration and transparent reporting that let you actually trust a result. That’s a grade-D human claim, not because Russian research is inherently suspect, but because the data as published can’t be independently verified or reproduced.

Underneath, there’s a mechanism worth acknowledging. In cell and animal systems, Selank alters the expression of genes involved in GABAergic neurotransmission and touches serotonergic signaling — plausible routes for an anxiolytic effect. That earns it scientific interest. It does not, on its own, tell you what a dose does to a human’s anxiety over weeks, which is the only question that matters for someone considering it.

Why the gap matters

It’s tempting to treat “used for decades in Russia” as if it were equivalent to “proven.” It isn’t. Long clinical use under a different regulatory system is not the same as replicated, transparently reported evidence — plenty of widely used treatments have collapsed once subjected to rigorous independent trials. When the verifiable human data amounts to a few small studies you can’t fully audit, the intellectually honest position is that Selank is unproven, and its reputation as a clean benzodiazepine substitute is running well ahead of the evidence.

The regulatory and sourcing reality

Selank is not approved in the US, the EU, or most of the world; its approvals are confined to a couple of post-Soviet countries. The FDA has placed it on its list of bulk substances for compounding that may present significant safety risks, citing concerns typical of this class — peptide impurities, characterization difficulty, and absent human safety data — and it falls under WADA’s unapproved-substance framework for athletes.

What you can actually buy is therefore a gray-market research chemical, usually a nasal spray or vial labeled “not for human consumption,” with no oversight of purity, dose, or sterility. You’d be self-treating anxiety with an unverified peptide from an unaccountable supplier.

The honest bottom line

Selank is a legitimately interesting research peptide and a poor way to treat your anxiety today. The mechanism is plausible and the domestic trial is suggestive, but “suggestive and un-replicated” is not a foundation for putting an unregulated peptide up your nose. Anxiety has genuinely evidence-backed treatments — therapy, exercise, and, where appropriate, medications with real trial support and a clinician monitoring them. Selank belongs in a conversation about what’s actually known, not in a package from a peptide vendor.